By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Neuren Pharmaceuticals Limited 

Level 3
2-6 Park Avenue
Grafton  Auckland    New Zealand
Phone: 64-9-367-7167, Ext 82308 Fax: 64-9-367-7186



Company News
Neuren Pharma’s Phase II Trial Of Trofinetide Demonstrates Significant Clinical Benefit In Pediatric Rett Syndrome 3/27/2017 8:14:51 AM
Neuren Pharmaceuticals Limited's NNZ-2566 Successful In Demonstrating Clinical Benefit In Rett Syndrome Phase 2 Trial 11/13/2014 11:22:24 AM
Neuren Pharmaceuticals Limited Appoints Joseph Horrigan, M.D., as VP of Clinical Development and Medical Affairs 8/10/2012 9:51:31 AM
Noble Life Sciences Inc. Announces Collaboration With Perseis Therapeutics -- Noble to Manage Neuren Pharmaceuticals Limited Subsidiary's Oncology Program 7/10/2012 8:19:55 AM
Neuren Pharmaceuticals Limited Holds Pre-IND Meeting on Proposed Rett Syndrome Clinical Trials With FDA 5/17/2012 8:21:22 AM
Neuren Pharmaceuticals Limited To Get US$5.5M Additional Funding for US Army Clinical Trial of NNZ-2566 9/5/2008 9:44:14 AM
Neuren Pharmaceuticals Limited Announce Glypromate(R) and NNZ-2566 Included in 10 Most Promising Neuroscience Projects by Windhover Information Inc. 7/21/2008 9:21:31 AM
Neuren Pharmaceuticals Limited Raises A$7.1M in Rights Issue 2/11/2008 12:07:00 PM
US Department of Defense Approves Funding for Neuren Pharmaceuticals Limited NNZ-2566 Trials 1/21/2008 11:16:20 AM
Neuren Pharmaceuticals Limited Announces A$10.1 Million Non-Renounceable Rights Issue 12/19/2007 10:34:21 AM